Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
|Articles|March 30, 2023
- March 2023
- Volume 89
- Issue 3
Pharmacist Pet Peeves: March 2023
Pharmacists need food too, you know.
Advertisement
Hangry
When patients get mad that you’re closing for lunch.
Articles in this issue
over 3 years ago
Heart Health OTC Cases: March 2023over 3 years ago
Pharmacy Times Interactive Case Studies: March 2023 Issueover 3 years ago
Rx Product News: March 2023over 3 years ago
OTC Product News: March 2023over 3 years ago
Rolvedon From Spectrum Pharmaceuticals, Incover 3 years ago
Generic Product News: March 2023over 3 years ago
Workforce Shortages Present Serious Challengesover 3 years ago
COVID-19 Public Health Emergency Declarations Near Endover 3 years ago
Generic Product News: MarchAdvertisement
Related to this article
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
Pharmacists make a difference in patients’ lives through MTM services.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
Oncology Pharmacists Reduce Adverse Drug Reactions in Hematologic Cancer Care
4
What Pharmacists Should Know About Sea Buckthorn for Respiratory Health
5